What is the suggested dosage of Lutein from the AREDS2 recommendations?

The Age-Related Eye Disease Study 2 (AREDS2) made significant contributions to our understanding of nutritional supplementation for age-related macular degeneration (AMD). One of the primary findings regarding lutein was that a dosage of 10 mg was recommended. This was based on evidence demonstrating that lutein, along with zeaxanthin, could play a protective role in the progression of AMD. The inclusion of lutein at this level was thought to effectively replace beta-carotene in the original AREDS formulation, contributing positively to visual health outcomes without the risks linked to beta-carotene in certain populations.

The selected dosage of 10 mg aligns with the overall goals of the AREDS2 study to optimize the benefits of supplementation for individuals at risk for advanced AMD. This level of lutein is significant in achieving the desired protective effects against the disease's progression while supporting overall eye health.